FAMU Bristol Myers Squibb Residency
OVERVIEW
This pharmaceutical industry residency program was founded in 2009 as a partnership between Florida A&M University and Bristol Myers Squibb. The vision of the residency is to attract and develop a diverse group of talented pharmacists who bring clinical expertise, innovative ideas, and dedication to improving patient outcomes.
The program provides a two-year residency in the therapeutic area of oncology in the first year and either immunology or oncology in the second year. This residency will provide the residents with a unique experience that bridges the gap between clinical practice and the pharmaceutical industry.
ABOUT BRISTOL MYERS SQUIBB
Bristol Myers Squibb is a global biopharmaceutical company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. They concentrate their research efforts in the following core therapeutic areas: Oncology, Hematology, Immunology, Cardiovascular, Fibrotic Diseases, and Neuroscience.
FAMU/BMS RESIDENCY PROGRAM APPLICATION PROCESS
To be admitted to the FAMU/BMS residency program, the candidate must have the following:
- Required: Doctor of Pharmacy (PharmD) degree from an accredited institution before the residency.
- Selected candidates must be licensed as a pharmacist before or within 90 days of starting the first year of the clinical residency.
- This program does not currently sponsor candidates for H-1B status to work as pharmacy residents.
- Letter of Intent
- Curriculum Vitae
- Unofficial Transcript
- Three Letters of Recommendation
- Selected candidates will be contacted for an onsite interview.
- One candidate will be selected for each position.
- All candidates will be notified of their status by December 2021.
For questions, please email FAMU@bms.com